P40 REAL-WORLD TREATMENT PATTERNS OF PATIENTS INITIATING THIRD-LINE THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA IN EUROPE

por Lehne, M., Kortüm, K.M., Zamagni, E., d’Estrube, T., Shukla, S., Zhuleku, E., Ghiani, M., Hanna, M., Maywald, U., Wilke, T., Perera, S.
Publicado 2023

Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?

por Rosenthal, A, Luthi, J, Belohlavek, M, Kortüm, K M, Mookadam, F, Mayo, A, Fonseca, R, Bergsagel, P L, Reeder, C B, Mikhael, J R, Stewart, A K
Publicado 2016

Genomic Characterization of High-Count MBL Cases Indicates that Early Detection of Driver Mutations and Subclonal Expansion are Predictors of Adverse Clinical Outcome

por Barrio, S., Shanafelt, T. D., Ojha, J., Chaffee, K. G., Secreto, C., Kortüm, K. M., Pathangey, S., Van-Dyke, D. L., Slager, S. L., Fonseca, R., Kay, N. E., Braggio, E.
Publicado 2016

P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN

por Munawar, U., Theuersbacher, J., Haertle, L., Zhou, X., Han, S., Regensburger, A., Mersi, J., Bittrich, M., Seifert, F., Haider, M.S., Nerreter, S., Vogt, C., Teufel, E., Einsele, H., Rasche, L., Kampik, D., Kortüm, K.M.
Publicado 2023

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL

por Nooka, A., Cohen, A., Lee, H., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E., Chaudhry, M., Hultcrantz, M., Kortüm, K.M., Richardson, P., Popat, R., Sborov, D., Hakim, S., Lewis, E., Bhushan, B., Gorsh, B., Gupta, I., Opalinska, J., Lonial, S.
Publicado 2023

Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes

por Steinhardt, M. J., Wiercinska, E., Pham, M., Grigoleit, G. U., Mazzoni, A., Da-Via, M., Zhou, X., Meckel, K., Nickel, K., Duell, J., Krummenast, F. C., Kraus, S., Hopkinson, C., Weissbrich, B., Müllges, W., Stoll, G., Kortüm, K. M., Einsele, H., Bonig, H., Rasche, L.
Publicado 2020

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY C...

por Zhou, X., Besse, A., Peter, J., Steinhardt, M. J., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Xiao, X., Hornburger, H., Haertle, L., Mendez Lopez, M., Munawar, U., Riedel, A., Han, S., Maurits, E., Overkleeft, H. S., Florea, B., Einsele, H., Kortüm, K. M., Driessen, C., Besse, L., Rasche, L.
Publicado 2023

P52 RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA

por Zhou, X., Hofmann, A., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Truger, M., Engel, B., Xiao, X., Eisele, F., Weis, P., Barcic, A., Peter, J., Riedhammer, C., Steinhardt, M. J., Hornburger, H., Han, S., Haertle, L., Munawar, U., Mersi, J., Haferlach, C., Einsele, H., Kortüm, K. M., Rasche, L.
Publicado 2023